Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Oct 2013

Gatanaga Hiroyuki, Murakoshi Hayato, Hachiya Atsuko, Hayashida Tsunefusa, Chikata Takayuki, Ode Hirotaka, Tsuchiya Kiyoto, Sugiura Wataru, Takiguchi Masafumi, Oka Shinichi

Abstract excerpt

BACKGROUND: Rilpivirine is listed as an alternative key drug in current antiretroviral therapy (ART) guidelines. E138G/A/K in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are rilpivirine resistance-associated mutations and can be identified in a few ART-naive patients, although at low frequency. The 138th position in HIV-1 RT is located in one of the putative epitopes of human leukocyte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Epitopes, T-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Leukocytes, Mononuclear

Share to Nitriles

Share to Pyrimidines

Share to Rilpivirine

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 23797286
DOI: 10.1093/cid/cit430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.PMID 23797286Read ↗

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.Semantic proximity Read ↗

Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.Semantic proximity Read ↗

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.Semantic proximity Read ↗

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.Semantic proximity Read ↗

Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.Semantic proximity Read ↗

Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.Semantic proximity Read ↗

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.Semantic proximity Read ↗

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults.Semantic proximity Read ↗

Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Semantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.